

Status: Currently Official on 15-Feb-2025
Official Date: Official Prior to 2013
Document Type: USP Monographs
DocId: GUID-A028892B-70C8-4CE7-B3F5-DAF21D15D8D7_1_en-US
DOI: https://doi.org/10.31003/USPNF_M33182_01_01
DOI Ref: 4e1y1

© 2025 USPC
Do not distribute

Finasteride Tablets

» Finasteride Tablets contain not less than 95.0 percent and not more than 105.0 percent of finasteride ($C_{23}H_{36}N_2O_2$).

Packaging and storage—Preserve in tight, light-resistant containers, and store at controlled room temperature.

USP REFERENCE STANDARDS (11)—

[USP Finasteride RS](#)

Identification—The retention time of the major peak in the chromatogram of the *Assay preparation* corresponds to that in the chromatogram of the *Standard preparation*, as obtained in the *Assay*.

DISSOLUTION (711)—

Medium: water; 900 mL.

Apparatus 2: 50 rpm.

FOR PRODUCTS LABELED AS 5-MG TABLETS—

Time: 45 minutes.

Determine the amount of $C_{23}H_{36}N_2O_2$ dissolved by employing the following method.

Mobile phase—Prepare a filtered and degassed mixture of acetonitrile and water (29:21). Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

Diluting solution—Prepare a solution of acetonitrile and water (7:3).

Standard solution—Dissolve an accurately weighed quantity of [USP Finasteride RS](#) in *Diluting solution*, and dilute quantitatively, and stepwise if necessary, with *Diluting solution* to obtain a solution having a known concentration approximately equivalent to the sample under test.

Chromatographic system (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 220-nm detector and a 4.6-mm × 5-cm column that contains packing L1. The column temperature is maintained at 45°. The flow rate is about 2 mL per minute. Chromatograph the *Standard solution*, and record the peak responses as directed for *Procedure*: the capacity factor, *k'*, is not less than 2.0; the column efficiency is greater than 1000 theoretical plates; the tailing factor is less than 2; and the relative standard deviation for replicate injections is less than 2.0%.

Procedure—Separately inject equal volumes (about 200 μ L) of the solution under test and the *Standard solution* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity of $C_{23}H_{36}N_2O_2$ dissolved.

Tolerances—Not less than 75% (*Q*) of the labeled amount of $C_{23}H_{36}N_2O_2$ is dissolved in 45 minutes.

FOR PRODUCTS LABELED AS 1-MG TABLETS—

Time: 30 minutes.

Mobile phase—Prepare a degassed mixture of acetonitrile and water (11:9). Make adjustments if necessary (see *System Suitability* under [Chromatography \(621\)](#)).

Diluting solution—Prepare a solution of water and acetonitrile (7:3).

Standard solution—Dissolve an accurately weighed quantity of [USP Finasteride RS](#) in *Diluting solution*, to obtain a solution having a known concentration of 0.1 mg per mL. Dilute this solution quantitatively, and stepwise if necessary, in 0.5% sodium lauryl sulfate to obtain a solution containing 0.001 mg of finasteride per mL.

Chromatographic system (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 220-nm detector and a 4.6-mm × 15-cm column that contains 5- μ m packing L11. The column temperature is maintained at 45°. The flow rate is about 1.5 mL per minute.

Chromatograph the *Standard solution*, and record the peak responses as directed for *Procedure*: the column efficiency is not less than 5000 theoretical plates; the tailing factor is not more than 2; and the relative standard deviation for replicate injections is not more than 2%.

Procedure—Separately inject equal volumes (about 100 μ L) of the solution under test and the *Standard solution* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity of finasteride ($C_{23}H_{36}N_2O_2$) dissolved.

Tolerances—Not less than 80% (Q) of the labeled amount of $C_{23}H_{36}N_2O_2$ is dissolved in 30 minutes.

UNIFORMITY OF DOSAGE UNITS (905): meet the requirements.

Assay—

Mobile phase—Prepare a filtered and degassed mixture of 2.5 mM phosphoric acid and acetonitrile (1:1). Make adjustments if necessary (see System Suitability under [Chromatography \(621\)](#)).

Diluting solution—Prepare a solution of acetonitrile and water (7:3).

Standard preparation—Dissolve an accurately weighed quantity of [USP Finasteride RS](#) in Diluting solution, and dilute quantitatively, and stepwise if necessary, with Diluting solution to obtain a solution having a known concentration of about 100 μ g per mL.

Assay preparation—Weigh and finely powder not fewer than 20 Tablets. Transfer an amount of powder equivalent to about 10 mg of finasteride, accurately weighed, to a 100-mL volumetric flask, dissolve in and dilute with Diluting solution to volume, and mix.

Chromatographic system (see [CHROMATOGRAPHY \(621\)](#))—The liquid chromatograph is equipped with a 240-nm detector and a 4.6-mm \times 10.0-cm column that contains packing L1. The column temperature is maintained at 45°. The flow rate is about 1.5 mL per minute. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the capacity factor, k' , is not less than 2.0; the column efficiency is not less than 1000 theoretical plates; the tailing factor is not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%.

Procedure—Separately inject equal volumes (about 20 μ L) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of finasteride ($C_{23}H_{36}N_2O_2$) in the portion of Tablets taken by the formula:

$$100C(r_u/r_s)$$

in which C is the concentration, in mg per mL, of [USP Finasteride RS](#) in the Standard preparation; and r_u and r_s are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
FINASTERIDE TABLETS	Documentary Standards Support	SM52020 Small Molecules 5

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 32(6)

Current DocID: GUID-A028892B-70C8-4CE7-B3F5-DAF21D15D8D7_1_en-US

DOI: https://doi.org/10.31003/USPNF_M33182_01_01

DOI ref: [4e1y1](#)